Burosumab - new potent treatment for X-linked hypophosphatemia and tumor-induced osteomalacia
Introduction and purpose: Elevated FGF23 in X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) leads to systemic hypophosphatemia, several musculoskeletal manifestations and rickets in children. In this review we describe advances in the management of XLH and TIO using burosumab, w...
Saved in:
Main Authors: | Magda Wojtuś (Author), Sebastian Tomaszuk (Author), Karolina Wąsik (Author) |
---|---|
Format: | Book |
Published: |
Kazimierz Wielki University,
2023-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of burosumab on lower limb alignment in children with X-linked hypophosphatemia
by: David B. Frumberg, MD, FAAOS, et al.
Published: (2024) -
Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
by: Silvia Martín Ramos, et al.
Published: (2020) -
Psilocybin - new remedy for patients with psychiatric disorders? Critical analysis of the current state of knowledge
by: Karolina Wąsik, et al.
Published: (2023) -
Nutritional factors in the prevention and treatment of gout
by: Sebastian Tomaszuk, et al.
Published: (2023) -
Impact of soy isoflavones on the prevention and treatment of obesity
by: Karolina Wąsik, et al.
Published: (2024)